AlphaQuest LLC Grows Position in SI-BONE, Inc. (NASDAQ:SIBN)

AlphaQuest LLC grew its stake in SI-BONE, Inc. (NASDAQ:SIBN) by 13,950.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,662 shares of the company’s stock after purchasing an additional 11,579 shares during the period. AlphaQuest LLC’s holdings in SI-BONE were worth $164,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Champlain Investment Partners LLC lifted its position in shares of SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after buying an additional 358,821 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of SI-BONE by 35.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company’s stock valued at $11,791,000 after buying an additional 220,555 shares in the last quarter. Pier Capital LLC lifted its position in shares of SI-BONE by 23.6% during the 3rd quarter. Pier Capital LLC now owns 465,898 shares of the company’s stock valued at $6,513,000 after buying an additional 88,897 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of SI-BONE during the 4th quarter valued at approximately $1,233,000. Finally, Millrace Asset Group Inc. purchased a new position in shares of SI-BONE during the 3rd quarter valued at approximately $1,056,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SIBN shares. Truist Financial reiterated a “buy” rating and set a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Needham & Company LLC increased their price objective on SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $24.50.

SI-BONE Stock Up 3.2 %

NASDAQ SIBN opened at $15.22 on Tuesday. The business has a fifty day moving average price of $16.56 and a 200 day moving average price of $14.84. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $19.16. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The company has a market cap of $646.13 million, a P/E ratio of -16.54 and a beta of 1.17.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. Research analysts anticipate that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other SI-BONE news, CFO Anshul Maheshwari sold 5,304 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the sale, the chief financial officer now directly owns 189,319 shares of the company’s stock, valued at $2,633,427.29. This trade represents a 2.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total value of $51,013.00. Following the transaction, the insider now owns 222,814 shares of the company’s stock, valued at approximately $3,097,114.60. This represents a 1.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,311 shares of company stock valued at $130,356 in the last three months. 3.90% of the stock is currently owned by insiders.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.